부산대학교 도서관

Harvey-Jones, E; Raghunandan, M; Robbez-Masson, L; Magraner-Pardo, L; Alaguthurai, T; Yablonovitch, A; Yen, J; Xiao, H; Brough, R; Frankum, J; Song, F; Yeung, J; Savy, T; Gulati, A; Alexander, J; Kemp, H; Starling, C; Konde, A; Marlow, R; Cheang, M; Proszek, P; Hubank, M; Cai, M; Trendell, J; Lu, R; Liccardo, R; Ravindran, N; Llop-Guevara, A; Rodriguez, O; Balmana, J; Lukashchuk, N; Dorschner, M; Drusbosky, L; Roxanis, I; Serra, V; Haider, S; Pettitt, SJ; Lord, CJ; Tutt, ANJ

Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Life Science Weekly. June 17, 2014, p2550

Seed G; The Institute of Cancer Research, London, UK.; Beije N; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.; Yuan W; The Institute of Cancer Research, London, UK.; Bertan C; The Institute of Cancer Research, London, UK.; Goodall J; The Institute of Cancer Research, London, UK.; Lundberg A; The Institute of Cancer Research, London, UK.; Tyler M; The Institute of Cancer Research, London, UK.; Figueiredo I; The Institute of Cancer Research, London, UK.; Pereira R; The Institute of Cancer Research, London, UK.; Baker C; The Institute of Cancer Research, London, UK.; Bogdan D; The Institute of Cancer Research, London, UK.; Gallagher L; The Institute of Cancer Research, London, UK.; Cieslik JP; Heinrich Heine University, Düsseldorf, Germany.; Greening S; The Institute of Cancer Research, London, UK.; Lambros M; The Institute of Cancer Research, London, UK.; Neves R; Heinrich Heine University, Düsseldorf, Germany.; Magraner-Pardo L; The Institute of Cancer Research, London, UK.; Fowler G; The Institute of Cancer Research, London, UK.; Ebbs B; The Institute of Cancer Research, London, UK.; Miranda S; The Institute of Cancer Research, London, UK.; Flohr P; The Institute of Cancer Research, London, UK.; Bianchini D; The Royal Marsden NHS Foundation Trust, London, UK.; Rescigno P; The Institute of Cancer Research, London, UK.; Porta N; The Institute of Cancer Research, London, UK.; Hall E; The Institute of Cancer Research, London, UK.; Gurel B; The Institute of Cancer Research, London, UK.; Tunariu N; The Royal Marsden NHS Foundation Trust, London, UK.; Sharp A; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.; Pettit S; The Institute of Cancer Research, London, UK.; Stoecklein NH; Heinrich Heine University, Düsseldorf, Germany.; Sandhu S; The Royal Marsden NHS Foundation Trust, London, UK.; Quigley D; UCSF, San Francisco, CA, USA.; Lord CJ; The Institute of Cancer Research, London, UK.; Mateo J; Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Carreira S; The Institute of Cancer Research, London, UK.; de Bono J; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: johann.de-bono@icr.ac.uk.

Publisher: Cell Press Country of Publication: United States NLM ID: 101130617 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-3686 (Electronic) Linking ISSN: 15356108 NLM ISO Abbreviation: Cancer Cell Subsets: MEDLINE

Mur, P; Garcia-Mulero, S; del Valle, J; Magraner-Pardo, L; Vidal, A; Pineda, M; Cinnirella, G; Martin-Ramos, E; Pons, T; Lopez-Doriga, A; Belhadj, S; Feliubadalo, L; Munoz-Torres, PM; Navarro, M; Grau, E; Darder, E; Llort, G; Sanz, J; Cajal, TRY; Balmana, J; Brunet, J; Moreno, V; Piulats, JM; Matias-Guiu, X; Sanz-Pamplona, R; Aligue, R; Capella, G; Lazaro, C; Valle, L

GENETICS IN MEDICINE
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
r-IIB SANT PAU: Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí

Reyes-González J; Precision Translational Oncology Laboratory, National Institute of Genomic Medicine, Mexico City, Mexico.; Barajas-Olmos F; Immunogenomics and Metabolic Diseases Laboratory, National Institute of Genomic Medicine, Mexico City, Mexico.; García-Ortiz H; Immunogenomics and Metabolic Diseases Laboratory, National Institute of Genomic Medicine, Mexico City, Mexico.; Magraner-Pardo L; Gene Function Team, The Institute of Cancer Research (ICR), London, UK.; Pons T; Department of Immunology and Oncology, National Center for Biotechnology, Spanish National Research Council (CNB-CSIC), Madrid, Spain.; Moreno S; Radioneurosurgery Unit, National Institute of Neurology and Neurosurgery; Mexico City, Mexico.; Aguirre-Cruz L; Neuroendocrinology Laboratory, National Institute of Neurology and Neurosurgery; Mexico City, Mexico.; Reyes-Abrahantes A; Precision Translational Oncology Laboratory, National Institute of Genomic Medicine, Mexico City, Mexico.; Martínez-Hernández A; Immunogenomics and Metabolic Diseases Laboratory, National Institute of Genomic Medicine, Mexico City, Mexico.; Contreras-Cubas C; Immunogenomics and Metabolic Diseases Laboratory, National Institute of Genomic Medicine, Mexico City, Mexico.; Barrios-Payan J; Department of Pathology, National Institute of Medical Sciences and Nutrition Salvador Zubiran, Mexico City, Mexico.; Ruiz-Garcia H; Department of Neurosurgery and Brain Tumor Stem Cell Research Laboratory, Mayo Clinic, Jacksonville, Florida,USA.; Hernandez-Pando R; Department of Pathology, National Institute of Medical Sciences and Nutrition Salvador Zubiran, Mexico City, Mexico.; Quiñones-Hinojosa A; Department of Neurosurgery and Brain Tumor Stem Cell Research Laboratory, Mayo Clinic, Jacksonville, Florida,USA.; Orozco L; Immunogenomics and Metabolic Diseases Laboratory, National Institute of Genomic Medicine, Mexico City, Mexico.; Abrahantes-Pérez MDC; Precision Translational Oncology Laboratory, National Institute of Genomic Medicine, Mexico City, Mexico.

Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication Model: Print Cited Medium: Internet ISSN: 1523-5866 (Electronic) Linking ISSN: 15228517 NLM ISO Abbreviation: Neuro Oncol Subsets: MEDLINE

Mur P; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. pmur@catsalut.cat.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. pmur@catsalut.cat.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. pmur@catsalut.cat.; Department of Health of Catalonia, Catalan Cancer Plan, Barcelona, Spain. pmur@catsalut.cat.; Viana-Errasti J; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; García-Mulero S; Department of Health of Catalonia, Catalan Cancer Plan, Barcelona, Spain.; Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.; Magraner-Pardo L; The CRUK Gene Function Laboratory and The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research (ICR), London, UK.; Muñoz IG; Protein Crystallography Unit, Structural Biology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain.; Pons T; Department of Immunology and Oncology, National Center for Biotechnology (CNB-CSIC), Spanish National Research Council, Madrid, Spain.; Capellá G; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Pineda M; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Feliubadaló L; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Valle L; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. lvalle@idibell.cat.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. lvalle@idibell.cat.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. lvalle@idibell.cat.

Publisher: BioMed Central Country of Publication: England NLM ID: 101475844 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-994X (Electronic) Linking ISSN: 1756994X NLM ISO Abbreviation: Genome Med Subsets: MEDLINE

Piccolo P.; Sabatino V.; Mithbaokar P.; Polishchuck E.; Law S. K.; Magraner-Pardo L.; Pons T.; Polishchuck R.; Brunetti-Pierri N.

Mol Genet Metab Rep
Digital.CSIC: Repositorio Institucional del CSIC
Consejo Superior de Investigaciones Científicas (CSIC)
Digital.CSIC. Repositorio Institucional del CSIC
instname
Molecular Genetics and Metabolism Reports, Vol 21, Iss, Pp-(2019)

Magraner-Pardo L; Pelechano V; Coloma M; Tordera V

BMC Genomics

Mur P; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Magraner-Pardo L; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Center (CNIO), Madrid, Spain.; García-Mulero S; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain.; Díez-Villanueva A; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Del Valle J; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Ezquerro E; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Lázaro C; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Capellá G; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Moreno V; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain.; Sanz-Pamplona R; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Pons T; Department of Immunology and Oncology, National Center for Biotechnology (CNB-CSIC), Spanish National Research Council, Madrid, Spain.; Valle L; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. lvalle@idibell.cat.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. lvalle@idibell.cat.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. lvalle@idibell.cat.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 9302235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5438 (Electronic) Linking ISSN: 10184813 NLM ISO Abbreviation: Eur J Hum Genet Subsets: MEDLINE

Mur P; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; García-Mulero S; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Del Valle J; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Magraner-Pardo L; Prostate Cancer Clinical Research Unit. Spanish National Cancer Research Center (CNIO), Madrid, Spain.; Vidal A; Department of Pathology, Bellvitge University Hospital, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Pineda M; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Cinnirella G; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Martín-Ramos E; Department of Biomedical Sciences, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain.; Pons T; Department of Immunology and Oncology, National Center for Biotechnology (CNB-CSIC), Spanish National Research Council, Madrid, Spain.; López-Doriga A; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.; Belhadj S; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Feliubadaló L; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Munoz-Torres PM; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Navarro M; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Grau E; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Darder E; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBGi, Girona, Spain.; Llort G; Department of Medical Oncology, Parc Taulí, Hospital Universitari Parc Taulí, Sabadell, Barcelona, Spain.; Consorci Sanitari de Terrassa, Terrasa, Barcelona, Spain.; Sanz J; Genetic Counseling Unit, Medical Oncology Department, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Spain.; Ramón Y Cajal T; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.; Balmana J; Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Brunet J; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBGi, Girona, Spain.; Moreno V; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain.; Piulats JM; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Medical Oncology, Bellvitge University Hospital, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Matías-Guiu X; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Pathology, Bellvitge University Hospital, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Sanz-Pamplona R; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.; Aligué R; Department of Biomedical Sciences, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain.; Capellá G; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Lázaro C; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Valle L; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. lvalle@idibell.cat.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. lvalle@idibell.cat.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. lvalle@idibell.cat.

Publisher: Elsevier Country of Publication: United States NLM ID: 9815831 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1530-0366 (Electronic) Linking ISSN: 10983600 NLM ISO Abbreviation: Genet Med Subsets: MEDLINE

Magraner-Pardo L; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Center (CNIO), 28029 Madrid, Spain.; Gobelli D; Department of Cell Biology, Histology and Pharmacology, University of Valladolid, 47005 Valladolid, Spain.; Unit of Excellence, Institute of Biology and Molecular Genetics, University of Valladolid and CSIC, 47003 Valladolid, Spain.; de la Fuente MA; Department of Cell Biology, Histology and Pharmacology, University of Valladolid, 47005 Valladolid, Spain.; Unit of Excellence, Institute of Biology and Molecular Genetics, University of Valladolid and CSIC, 47003 Valladolid, Spain.; Pons T; Department of Immunology and Oncology, National Center for Biotechnology (CNB-CSIC), Spanish National Research Council, 28049 Madrid, Spain.; Simarro M; Unit of Excellence, Institute of Biology and Molecular Genetics, University of Valladolid and CSIC, 47003 Valladolid, Spain.; Department of Department of Nursing, University of Valladolid, 47005 Valladolid, Spain.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Magraner-Pardo L; Prostate Cancer Clinical Unit, Spanish National Cancer Research Center (CNIO), Madrid, Spain.; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Cambridge, UK.; Laskowski RA; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Cambridge, UK.; Pons T; Department of Immunology and Oncology, National Center for Biotechnology, Spanish National Research Council (CNB-CSIC), Madrid, Spain.; Thornton JM; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Cambridge, UK. thornton@ebi.ac.uk.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Castro E; 1 Prostate Cancer Clinical Unit, Spanish National Cancer Research Center, Madrid, Spain.; 2 Hospital Universitario Quiron, Madrid, Spain.; Romero-Laorden N; 1 Prostate Cancer Clinical Unit, Spanish National Cancer Research Center, Madrid, Spain.; 3 Hospital Universitario La Princesa, Madrid, Spain.; Del Pozo A; 4 Institute of Medical and Molecular Genetics, Hospital Universitario La Paz, and CIBERER Instituto de Salud Carlos III, Madrid, Spain.; Lozano R; 1 Prostate Cancer Clinical Unit, Spanish National Cancer Research Center, Madrid, Spain.; 5 CNIO_IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Málaga, Málaga Spain.; Medina A; 6 Centro Oncológico de Galicia, Coruña, Spain.; Puente J; 7 Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain.; Piulats JM; 8 Institut Català d'Oncologia, Bellvitge Biomedical Research Institute, Barcelona, Spain.; Lorente D; 9 Hospital Universitario La Fe, Valencia, Spain.; Saez MI; 5 CNIO_IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Málaga, Málaga Spain.; 10 Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Málaga, Spain.; Morales-Barrera R; 11 Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.; Gonzalez-Billalabeitia E; 12 Hospital Morales Messeguer-IMIB, UCAM, Murcia, Spain.; Cendón Y; 1 Prostate Cancer Clinical Unit, Spanish National Cancer Research Center, Madrid, Spain.; 13 Universidad Autónoma de Madrid, Madrid, Spain.; García-Carbonero I; 14 Hospital Virgen de la Salud, Toledo, Spain.; Borrega P; 15 Hospital San Pedro de Alcántara, Cáceres, Spain.; Mendez Vidal MJ; 16 Hospital Universitario Reina Sofia, Córdoba, Spain.; Montesa A; 5 CNIO_IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Málaga, Málaga Spain.; 10 Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Málaga, Spain.; Nombela P; 1 Prostate Cancer Clinical Unit, Spanish National Cancer Research Center, Madrid, Spain.; Fernández-Parra E; 17 Hospital Universitario de Valme, Seville, Spain.; Gonzalez Del Alba A; 18 Hospital Universitario Son Espases, Palma de Mallorca, Spain.; Villa-Guzmán JC; 19 Hospital General Universitario de Ciudad Real, Ciudad Real, Spain.; Ibáñez K; 4 Institute of Medical and Molecular Genetics, Hospital Universitario La Paz, and CIBERER Instituto de Salud Carlos III, Madrid, Spain.; Rodriguez-Vida A; 20 Hospital del Mar, Barcelona, Spain.; Magraner-Pardo L; 1 Prostate Cancer Clinical Unit, Spanish National Cancer Research Center, Madrid, Spain.; Perez-Valderrama B; 21 Hospital Universitario Virgen del Rocío, Seville, Spain.; Vallespín E; 4 Institute of Medical and Molecular Genetics, Hospital Universitario La Paz, and CIBERER Instituto de Salud Carlos III, Madrid, Spain.; Gallardo E; 22 Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell, Spain.; Vazquez S; 23 Hospital Universitario Lucus Augusti, Lugo, Spain.; Pritchard CC; 24 University of Washington Medical Center, Seattle, WA.; Lapunzina P; 4 Institute of Medical and Molecular Genetics, Hospital Universitario La Paz, and CIBERER Instituto de Salud Carlos III, Madrid, Spain.; Olmos D; 1 Prostate Cancer Clinical Unit, Spanish National Cancer Research Center, Madrid, Spain.; 5 CNIO_IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Málaga, Málaga Spain.

Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

Usach I; Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Valencia, Avda. V. Andrés Estellés, s/n, Burjassot, Valencia 46100, Spain.; Taléns-Visconti R; Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Valencia, Avda. V. Andrés Estellés, s/n, Burjassot, Valencia 46100, Spain.; Magraner-Pardo L; Fundación Centro de Innovación y Demostración Tecnológica, Paseo de la Castellana, 141, Madrid 28046, Spain.; Peris JE; Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Valencia, Avda. V. Andrés Estellés, s/n, Burjassot, Valencia 46100, Spain. Electronic address: jose.e.peris@uv.es.

Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 8207483 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-6351 (Electronic) Linking ISSN: 02786915 NLM ISO Abbreviation: Food Chem Toxicol Subsets: MEDLINE

Vicente-Muñoz S; Structural Biochemistry Laboratory, Centro de Investigación Príncipe Felipe (CIPF), Eduardo Primo Yúfera, 3, 46012 València, Spain.; Romero P; Departament de Bioquímica i Biologia Molecular, Universitat de València, C/Dr. Moliner 50, 46100 Burjassot, València, Spain.; Magraner-Pardo L; Departament de Bioquímica i Biologia Molecular, Universitat de València, C/Dr. Moliner 50, 46100 Burjassot, València, Spain.; Martinez-Jimenez CP; Departament de Bioquímica i Biologia Molecular, Universitat de València, C/Dr. Moliner 50, 46100 Burjassot, València, Spain.; Tordera V; Departament de Bioquímica i Biologia Molecular, Universitat de València, C/Dr. Moliner 50, 46100 Burjassot, València, Spain.; Pamblanco M; Departament de Bioquímica i Biologia Molecular, Universitat de València, C/Dr. Moliner 50, 46100 Burjassot, València, Spain.

Publisher: John Wiley & Sons Ltd Country of Publication: England NLM ID: 101580716 Publication Model: eCollection Cited Medium: Print ISSN: 2211-5463 (Print) Linking ISSN: 22115463 NLM ISO Abbreviation: FEBS Open Bio Subsets: PubMed not MEDLINE